Therapies in ankylosing spondylitis-from clinical trials to clinical practice.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30445480.
- Also identified by DOI 10.1093/rheumatology/key152 and PMC identifier 6238222.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Until recently, the therapeutic options for patients suffering from active AS comprised NSAIDs and TNF inhibitor therapy. Although these are effective in a significant proportion of patients, not all patients respond and some are intolerant to these therapies. Therefore, there is a clear unmet treatment need in AS patients. This article reviews the evidence for targets currently being studied in AS. This includes the IL-12/23 inhibitor ustekinumab, the pan-Janus kinase inhibitor tofacitinib and the anti-IL-17A antibody secukinumab.
Medical subject headings
- Antibodies, Monoclonal
- Antirheumatic Agents
- Piperidines
- Pyrimidines
- Pyrroles
- Spondylitis, Ankylosing
- Ustekinumab